Replies to post #107915 on Biotech Values

[DewDiligence]

I don't imagine MNTA would have any greater a chance of getting an injunction than Sanofi did vs MNTA.

The two cases are dissimilar. SNY sued the FDA, not another company, and the suit had nothing whatsoever to do with patents. MNTA, on the other hand, could sue Teva for infringement of its Lovenox-characterization patents. I doubt that MNTA will ever need to file such a suit, but it’s nice to have a backup plan at the ready.